Abstract
Tuberculosis (TB) infects one-third of the world population. Despite 50 years of available drug treatments, TB continues to increase at a significant rate. The failure to control TB stems in part from the expense of delivering treatment to infected individuals and from complex treatment regimens. Incomplete treatment has fueled the emergence of multi-drug resistant (MDR) strains of Mycobacterium tuberculosis (Mtb). Reducing non-compliance by reducing the duration of chemotherapy will have a great impact on TB control. The development of new drugs that either kill persisting organisms, inhibit bacilli from entering the persistent phase, or convert the persistent bacilli into actively growing cells susceptible to our current drugs will have a positive effect. We are taking a multidisciplinary approach that will identify and characterize new drug targets that are essential for persistent Mtb. Targets are exposed to a battery of analyses including microarray experiments, bioinformatics, and genetic techniques to prioritize potential drug targets from Mtb for structural analysis. Our core structural genomics pipeline works with the individual laboratories to produce diffraction quality crystals of targeted proteins, and structural analysis will be completed by the individual laboratories. We also have capabilities for functional analysis and the virtual ligand screening to identify novel inhibitors for target validation. Our overarching goals are to increase the knowledge of Mtb pathogenesis using the TB research community to drive structural genomics, particularly related to persistence, develop a central repository for TB research reagents, and discover chemical inhibitors of drug targets for future development of lead compounds.
Keywords: free-interface diffusion screening chip, Virtual screening, ATP-phosphoribosyl transferase, Mycolic acid, Pantothenate Synthetase, Arginine Metabolism
Infectious Disorders - Drug Targets
Title: High Throughput Crystallography of TB Drug Targets
Volume: 7 Issue: 2
Author(s): T.R. Ioerger, J.C. Sacchettini, S. Wang, F.Wang, T.C. Terwilliger, B.W. Segelke, R. Sankaranarayanan, J.S. Lott, I. Krieger, C. Kim, M.N.G.James, W.R. Jacobs, A.C. Murillo, L. W. Hung, C.W. Goulding, C.R. Garen, D. Eisenberg, Yoon Song Cho, M.M. Cherney, L.T. Cherney, J.M. Berger, E.N. Baker, T. Alber and H.Y. Li
Affiliation:
Keywords: free-interface diffusion screening chip, Virtual screening, ATP-phosphoribosyl transferase, Mycolic acid, Pantothenate Synthetase, Arginine Metabolism
Abstract: Tuberculosis (TB) infects one-third of the world population. Despite 50 years of available drug treatments, TB continues to increase at a significant rate. The failure to control TB stems in part from the expense of delivering treatment to infected individuals and from complex treatment regimens. Incomplete treatment has fueled the emergence of multi-drug resistant (MDR) strains of Mycobacterium tuberculosis (Mtb). Reducing non-compliance by reducing the duration of chemotherapy will have a great impact on TB control. The development of new drugs that either kill persisting organisms, inhibit bacilli from entering the persistent phase, or convert the persistent bacilli into actively growing cells susceptible to our current drugs will have a positive effect. We are taking a multidisciplinary approach that will identify and characterize new drug targets that are essential for persistent Mtb. Targets are exposed to a battery of analyses including microarray experiments, bioinformatics, and genetic techniques to prioritize potential drug targets from Mtb for structural analysis. Our core structural genomics pipeline works with the individual laboratories to produce diffraction quality crystals of targeted proteins, and structural analysis will be completed by the individual laboratories. We also have capabilities for functional analysis and the virtual ligand screening to identify novel inhibitors for target validation. Our overarching goals are to increase the knowledge of Mtb pathogenesis using the TB research community to drive structural genomics, particularly related to persistence, develop a central repository for TB research reagents, and discover chemical inhibitors of drug targets for future development of lead compounds.
Export Options
About this article
Cite this article as:
T.R. Ioerger , J.C. Sacchettini , S. Wang , F.Wang , T.C. Terwilliger , B.W. Segelke , R. Sankaranarayanan , J.S. Lott , I. Krieger , C. Kim , M.N.G.James , W.R. Jacobs , A.C. Murillo , L. W. Hung , C.W. Goulding , C.R. Garen , D. Eisenberg , Yoon Song Cho , M.M. Cherney , L.T. Cherney , J.M. Berger , E.N. Baker , T. Alber and H.Y. Li , High Throughput Crystallography of TB Drug Targets, Infectious Disorders - Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/187152607781001853
DOI https://dx.doi.org/10.2174/187152607781001853 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Marine Microbes-Derived Anti-Bacterial Agents
Mini-Reviews in Medicinal Chemistry subject Index To Volume 3
Current Drug Targets Clinical Management of Drug-resistant Mycobacterium tuberculosis Strains: Pathogen-targeted Versus Host-directed Treatment Approaches
Current Pharmaceutical Biotechnology Effect of Vitamin D Supplementation in Type 2 Diabetes Patients with Tuberculosis: A Systematic Review
Current Diabetes Reviews The Economics of Polypharmacology: Fixed Dose Combinations and Drug Cocktails
Current Medicinal Chemistry Diagnosis and Treatment of Pulmonary Fungal Infections in Critically Ill Patients
Current Respiratory Medicine Reviews Should We Develop an Inhaled Anti-pneumococcal Vaccine for Adults?
Current Medicinal Chemistry - Anti-Infective Agents Antimicrobial Activities of Synthetic Arylidine Nicotinic and Isonicotinic Hydrazones
Letters in Drug Design & Discovery High Levels of CD57+CD28- T-Cells, Low T-Cell Proliferation and Preferential Expansion of Terminally Differentiated CD4+ T-Cells in HIVElite Controllers
Current HIV Research Essential Fatty Acids - A Review
Current Pharmaceutical Biotechnology Dibenzofurans from Lichens – A Pharmacological Overview
Current Topics in Medicinal Chemistry Targeting Inhibition of COX-2: A Review of Patents, 2002 - 2006
Recent Patents on Inflammation & Allergy Drug Discovery Compendious Review on Bioactive Constituents and Pharmacotherapeutic Profile of Heliotropium indicum Linn
The Natural Products Journal Anti-Infective Action of Immuno-modulating Polysaccharides (β-Glucan and Plantago Major L. Pectin) against Intracellular (Mycobacteria sp.) and Extracellular (Streptococcus Pneumoniae sp.) Respiratory Pathogens
Current Medicinal Chemistry - Anti-Infective Agents Maternal Sepsis 2010: Early Recognition and Aggressive Treatment with Early Goal Directed Therapy can Improve Maternal Outcomes
Current Women`s Health Reviews New Heterocyclic Hydrazones in the Search for Antitubercular Agents: Synthesis and In Vitro Evaluations
Letters in Drug Design & Discovery Editorial
Current Molecular Medicine Oxidative Stress and Antioxidant Potential of One Hundred Medicinal Plants
Current Topics in Medicinal Chemistry A Review of Molecular Modelling Studies of Dihydrofolate Reductase Inhibitors Against Opportunistic Microorganisms and Comprehensive Evaluation of New Models
Current Pharmaceutical Design Current Study of the Detection and Treatment Targets of Spinal Tuberculosis
Current Drug Targets